ArticleCirculation. Cardiovascular quality and outcomes2022

Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan.

Alexander T Sandhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.